Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics (EWTX)
NASDAQ:EWTX
EWTX Analyst Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
EWTX Stock 12 Month Forecast
Average Price Target
$37.00
▲(65.84% Upside)
| Highest Price Target$51.00 | Average Price Target$37.00 | Lowest Price Target$20.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Truist Financial
―
Buy
―
Reiterated
12/04/25
Evercore ISI
$30
Buy
34.47%
Upside
Reiterated
11/17/25
J.P. Morgan
$33→$34
Buy
52.40%
Upside
Reiterated
11/14/25
Piper Sandler
$51
Buy
128.60%
Upside
Reiterated
11/13/25
H.C. Wainwright
$42
Buy
88.26%
Upside
Reiterated
11/07/25
RBC Capital
$50
Buy
124.11%
Upside
Reiterated
11/06/25
Goldman Sachs
$20
Hold
-10.35%
Downside
Assigned
09/24/25
Leerink Partners
$50
Buy
124.11%
Upside
Reiterated
08/07/25
Analysts' Top Healthcare Picks: Immunic (IMUX), Edgewise Therapeutics (EWTX)We now wait for the GRAND CANYON topline readout in 4Q26. In DMD, EWTX thinks that a 10 mg dose appears to have a profile that can move forward to a Phase 3 study after several rounds of dose exploration. Recall, EWTX shared data earlier this year that demonstrated that patients who remained on 10 mg for the majority of the study were doing well on functional outcomes, with cohorts 2 and 3 showing a +2.2 difference on NSAA and +0.3 on SV95C vs. predicted natural history (here).
Raymond James
$46
Buy
106.19%
Upside
Reiterated
08/07/25
Scotiabank
$14
Hold
-37.25%
Downside
Reiterated
06/27/25
Stifel Nicolaus
$16
Hold
-28.28%
Downside
Reiterated
06/26/25
Guggenheim
$41
Buy
83.77%
Upside
Initiated
04/30/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Truist Financial
―
Buy
―
Reiterated
12/04/25
Evercore ISI
$30
Buy
34.47%
Upside
Reiterated
11/17/25
J.P. Morgan
$33→$34
Buy
52.40%
Upside
Reiterated
11/14/25
Piper Sandler
$51
Buy
128.60%
Upside
Reiterated
11/13/25
H.C. Wainwright
$42
Buy
88.26%
Upside
Reiterated
11/07/25
RBC Capital
$50
Buy
124.11%
Upside
Reiterated
11/06/25
Goldman Sachs
$20
Hold
-10.35%
Downside
Assigned
09/24/25
Leerink Partners
$50
Buy
124.11%
Upside
Reiterated
08/07/25
Analysts' Top Healthcare Picks: Immunic (IMUX), Edgewise Therapeutics (EWTX)We now wait for the GRAND CANYON topline readout in 4Q26. In DMD, EWTX thinks that a 10 mg dose appears to have a profile that can move forward to a Phase 3 study after several rounds of dose exploration. Recall, EWTX shared data earlier this year that demonstrated that patients who remained on 10 mg for the majority of the study were doing well on functional outcomes, with cohorts 2 and 3 showing a +2.2 difference on NSAA and +0.3 on SV95C vs. predicted natural history (here).
Raymond James
$46
Buy
106.19%
Upside
Reiterated
08/07/25
Scotiabank
$14
Hold
-37.25%
Downside
Reiterated
06/27/25
Stifel Nicolaus
$16
Hold
-28.28%
Downside
Reiterated
06/26/25
Guggenheim
$41
Buy
83.77%
Upside
Initiated
04/30/25
Best Analysts Covering Edgewise Therapeutics
1 Month
xxx
Success Rate
12/17 ratings generated profit
Average Return
+3.78%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.59% of your transactions generating a profit, with an average return of +3.78% per trade.
3 Months
xxx
Success Rate
11/17 ratings generated profit
Average Return
+31.96%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +31.96% per trade.
1 Year
Success Rate
14/24 ratings generated profit
Average Return
+74.48%
reiterated a buy rating 4 months ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +74.48% per trade.
2 Years
xxx
Success Rate
23/28 ratings generated profit
Average Return
+77.84%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 82.14% of your transactions generating a profit, with an average return of +77.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
EWTX Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
14
7
7
6
6
Buy
2
0
0
4
5
Hold
2
1
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
8
8
11
11
Each month's total comprises the sum of three months' worth of ratings.
EWTX Financial Forecast
EWTX Stock Forecast FAQ
What is EWTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Edgewise Therapeutics’s 12-month average price target is 37.00.
What is EWTX’s upside potential, based on the analysts’ average price target?
Edgewise Therapeutics has 65.84% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is EWTX a Buy, Sell or Hold?
Edgewise Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
What is Edgewise Therapeutics’s price target?
The average price target for Edgewise Therapeutics is 37.00. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $51.00 ,the lowest forecast is $20.00. The average price target represents 65.84% Increase from the current price of $22.31.
The highest analyst price target is $51.00 ,the lowest forecast is $20.00. The average price target represents 65.84% Increase from the current price of $22.31.
What do analysts say about Edgewise Therapeutics?
Edgewise Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of EWTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.